Manuel Litchman
Impact in
- Oncology top 10%
- Drug Transport and Resistance Mechanisms
- CAR-T cell therapy research
- Hematology top 10%
- Acute Myeloid Leukemia Research
Papers in
- Oncology 11
- Drug Transport and Resistance Mechanisms 8
- CAR-T cell therapy research 3
- Cancer Treatment and Pharmacology 3
-
- Acute Myeloid Leukemia Research 5
- Co-authors
- Branimir I. Šikić (4 shared papers)Ranjana H. Advani (4 shared papers)Martin S. Tallman (3 shared papers)Eric Davis (3 shared papers)Jacob M. Rowe (3 shared papers)Kathleen Dugan (3 shared papers)Peter H. Wiernik (3 shared papers)Elisabeth Paietta (3 shared papers)
- Journals
- Blood (5 papers)Journal of Clinical Oncology (3 papers)Leukemia (1 paper)Advances in experimental medicine and biology (1 paper)PubMed (1 paper)
- Partner nations
- United StatesSwitzerlandItaly
In The Last Decade
Manuel Litchman
11 papers receiving 533 citations
Peers
Comparison fields: 5 of 55
- Oncology 435
- Hematology 140
- Pediatrics, Perinatology and Child Health 147
- Pharmacology 47
- Genetics 50
Countries citing papers authored by Manuel Litchman
This map shows the geographic impact of Manuel Litchman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Litchman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Litchman more than expected).
Fields of papers citing papers by Manuel Litchman
This network shows the impact of papers produced by Manuel Litchman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Litchman. The network helps show where Manuel Litchman may publish in the future.
Co-authors
The 25 scholars most cited alongside Manuel Litchman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1999 | 124 | |
| 2 | 1999 | 109 | |
| 3 | 2000 | 66 | |
| 4 | 2001 | 65 | |
| 5 | A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. | 2001 | 62 |
| 6 | 1999 | 33 | |
| 7 | 2001 | 25 | |
| 8 | 2013 | 20 | |
| 9 | 2000 | 17 | |
| 10 | 2013 | 17 | |
| 11 | 2014 | 6 |
About Manuel Litchman
Manuel Litchman is a scholar working on Oncology, Hematology, Molecular Biology, Genetics and Pediatrics, Perinatology and Child Health, having authored 11 papers that have together received 544 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (8 papers), Acute Myeloid Leukemia Research (5 papers), CAR-T cell therapy research (3 papers), Cancer Treatment and Pharmacology (3 papers), Pharmacological Effects and Toxicity Studies (2 papers), Acute Lymphoblastic Leukemia research (2 papers), Hemoglobinopathies and Related Disorders (1 paper) and Histone Deacetylase Inhibitors Research (1 paper). The work is most often cited by research in Oncology (435 citations), Hematology (140 citations), Pediatrics, Perinatology and Child Health (147 citations), Pharmacology (47 citations) and Genetics (50 citations). Manuel Litchman has collaborated with scholars based in United States, Switzerland and Italy. Frequent co-authors include Branimir I. Šikić, Ranjana H. Advani, Martin S. Tallman, Eric Davis, Jacob M. Rowe, Kathleen Dugan, Peter H. Wiernik, Elisabeth Paietta, Peter L. Greenberg and Hussain I. Saba. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, Advances in experimental medicine and biology and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.